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The disease management approach to controlling 
asthma 
T: HAAHTELA 
Helsinki University Central Hospital, Helsinki, Finland 
Abstract Asthma has become an important public health issue worldwide and certain groups, such as children, are at 
particular riskofthe disease.Ofien asthma remains under-diagnosed and under-treated. Despite these worrying trends, 
the disease management approach to asthma control can help most asthma patients achieve a’normal’ way of life.The 
increased prevalence and greater diagnostic awareness of asthma have placed increased demands on healthcare re- 
sources, but effective asthma control can minimize the personal, social and economic burdens ofasthma. Early diagnosis 
and immediate anti-inflammatory treatment is the first step in gaining control ofsymptoms. A stepwise approach is then 
used to classify asthma severity and treatment, with the number and frequency of medications increasing (step up) as 
asthma severity increases and decreasing (step down) when asthma is under controLThis stepwise approach to asthma 
management necessitates regular review oftreatment once asthma is under control. However, effective asthma manage- 
ment is dependent on successful patient education, adherence to prescribed medication and good doctor-patient part- 
nerships. Current treatment guidelines recommend the use of a written asthma management plan that should be 
agreed between the doctor and patientThese plans should cover all aspects ofasthmatreatment, including prevention 
steps for long-term control and action steps to stop attacks once a worsening in asthma has been recognized.This com- 
prehensive approach to asthma management increases the likelihood ofachieving asthma control, which in turn reduces 
the need for emergency visits to the hospital or clinic and reduces the limitations on physical activity previously imposed 
by the condition. 
0 2002 Elsevier Science Ltd 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the air- 
ways that involves many cells and cellular elements. In 
susceptible individuals, this inflammation causes recur- 
rent episodes of coughing, wheezing, tightening of the 
chest and difficulty in breathing. Difficulty in breathing is 
caused by variable airflow obstruction when airways are 
exposed to various stimuli or triggers. 
An increase in the understanding of the pathophysi- 
ology of asthma has influenced the development of new 
pharmacotherapies. The use of pharmacotherapy in 
asthma helps prevent and control asthma symptoms, re- 
ducing the frequency and severity of asthma exacerba- 
tions and reversing airway obstruction. Asthma is not 
always progressive and early diagnosis and treatment 
with prescribed medication may help reduce or prevent 
progression (I). Asthma is also a variable disorder that 
changes in severity over short periods of time; the fre- 
quency of acute attacks also varies with time. These 
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changing characteristics make asthma management a 
challenge for both the doctor and patient. 
Given the highly variable nature of the disorder, it is 
important that patients have a good understanding of 
their condition and are able to recognize a worsening of 
asthma symptoms. Disease management programmes 
enable both the patient and physician to make thera- 
peutic, behavioural and environmental adjustments 
when the early signs of an asthma exacerbation appear. 
Patient co-operation and adherence to prescribed medi- 
cation and management programmes are essential in 
asthma management since daily monitoring and frequent 
treatment adjustments help optimize control in persis- 
tent asthma. Recent improvements in patient education 
and an increase in the level of patient involvement in their 
treatment programme should help achieve good asthma 
control with better doctor-patient partnerships and a 
more appropriate use of asthma medications. 
THE BURDEN OF ASTHMA 
Asthma is a major public health concern affecting over 
100 million people worldwide (2,3). The prevalence of 
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the disease differs greatly among affluent and non-afflu- 
ent populations, with a higher prevalence rate in affluent 
populations. Indeed, Australia has the greatest preva- 
lence worldwide. At this time there are insufficient data 
to determine what affects the prevalence rates (4). 
Despite significant advances in understanding the 
pathogenesis and pathophysiology of the disease, the 
prevalence of asthma in the general population is in- 
creasing and certain subgroups (e.g. children and young 
people) are at particular risk (3,5). A recent report on 
the prevalence of asthma in Scotland concluded that the 
prevalence of asthma in adults has increased by more 
than twofold in the last 20 years and this is seen largely 
in association with trends in atopy. Greater diagnostic 
awareness was not thought to account for the trend in 
atopic asthma (6).Changes in factors such as the severity 
of the disease, rather than prevalence, may account for 
the increased mortality, morbidity and number of hospi- 
tal admissions (7). Poorly controlled asthma is frequently 
due to inappropriate or insufficient medication and the 
costs of these inadequacies have considerable social and 
economic impact (4). 
The cost of asthma comprises both direct and indirect 
costs. The direct costs include all medical expenditure, 
including primary care and emergency room visits, and 
inpatient treatment. Of these costs, inpatient hospital 
expenditure and emergency care are consistently dispro- 
portionately high. Indirect costs are an estimate of lost 
productivity due to asthma or time taken off work to 
care for a family member with asthma. A number of re- 
cent reports estimate that indirect costs of asthma 
range from 39% to 49% of the total cost of the disease 
(8,9). In one study, indirect costs were reported to 
be twice as high as direct costs at all levels of asthma 
severity and a minority of severe asthmatics incurred 
41% of total asthma costs (IO). Therefore, reducing the 
indirect costs associated with asthma management will 
have a significant impact on the total cost of the disease. 
There is a large variation in the total cost of asthma 
among countries, but a cross-comparison between 
countries shows that hospitalization and emergency care 
are consistently high and the cost of medication is a key 
element of the healthcare costs. Cost comparisons be- 
tween industrialized countries, such as the USA, and 
more agricultural areas, such as South Africa, show that 
the total costs for asthma as a single condition currently 
account for l-2% of total healthcare expenditure (4). 
The social impact of asthma varies from country to 
country and across cultures.When asthma is poorly con- 
trolled, it affects patients’ social functioning and limits 
their involvement in various activities. All levels of asth- 
ma severity have a social impact and reduce the patient’s 
quality of life. Asthma management programmes are, 
therefore, designed to redress the negative social impact 
and have a positive impact on quality of life. Patients with 
chronic cough and wheezing may develop social stigma, 
whereas lost days at work due to asthma may result in a 
gradual loss of steady employment, which may lead to 
marginal jobs or unemployment (4). 
Occupational asthma is another contributor to the 
social burden of the disease (4,ll). A number of occupa- 
tions involve exposure to allergens and agents that can 
sensitize the airways and cause asthma.The incidence of 
occupational asthma is expected to increase with the in- 
troduction of new materials in the workplace, despite 
better regulation of occupational hazards. Once a work- 
er has become sensitized to an agent, it is essential that 
they have no future contact with the sensitizing agent; 
this may require redeployment. 
Asthma is a leading cause of hospital admissions for 
children in the USA, with a total of I .9 million days of 
inpatient treatment.Childhood asthma is also estimated 
to result in 7.3 million days confined to bed and IO. I mil- 
lion missed school days per year (12). Days absent from 
school is only one measure of the social impact of asthma 
and other factors, such as associated pain and number of 
days with asthma symptoms, are also used to obtain a 
fuller impression of how asthma affects children. It is re- 
cognized that missed education may have long-term con- 
sequences on academic performance, social functioning 
and self-esteem (4). Poorly controlled asthma in children 
affects all immediate family members, particularly par- 
ents who take time off work to care for a child at home. 
DIAGNOSIS OF ASTHMA 
Diagnosing asthma is still a challenge and for some 
patients correct diagnosis may take years (13). Failure to 
diagnose asthma may lead to the prescription of 
inappropriate and ineffective treatments, such as anti- 
biotics or cough medication, thus delaying the start of 
effective asthma therapy Some patient populations are 
particularly difficult to diagnose and these include: small 
children, the elderly, smokers, people with seasonal 
asthma and those with cough-variant asthma. Asthma 
also remains under-diagnosed because some people do 
not seek medical advice. 
Initial assessment and diagnosis of asthma is the first 
step in gaining early control of symptoms. In order to di- 
agnose asthma, the presence of episodic airflow obstruc- 
tion, which is at least partly reversible, must be 
confirmed. The patient’s medical and family history also 
helps assess the patient’s allergic status and should reveal 
predisposing factors for developing asthma. Pulmonary 
function tests are needed to ensure a correct diagnosis 
of asthma (14). Other diseases of the airways need to be 
excluded and these include chronic obstructive pulmon- 
ary disease, bronchiectasis, interstitial pulmonary fibro- 
sis, recurrent respiratory infections, laryngeal 
dysfunction, cystic fibrosis and localized obstruction of 
the airways. Asthma should, however, always be sus- 
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petted if the patient has wheezing, chest tightness or a 
prolonged cough. 
The diagnosis of asthma in children is more difficult 
than in adults (14) because they may only have asthma 
symptoms along with viral illness, exercise or as cough- 
ing at night. The presence of night-time coughing that 
awakens the child in the early hours of the morning is al- 
most always asthma (4). Asthma should also be consid- 
ered if a child has a cold with a cough that lasts for more 
than IO days. Current guidelines recommend that recur- 
rent wheezing in infants, with or without atopy, should 
be treated as asthma (14). 
CLASSIFICATION OF DISEASE 
SEVERITY 
The severity of asthma can be highly variable in any 
patient and the need for regular reviews is now recog- 
nized in the current guidelines (5,14). Clinical assessment 
and self-assessment are the primary methods of moni- 
toring asthma and they are instrumental in establishing 
whether the goals of treatment are being met. 
Assessing the severity of a patient’s asthma helps the 
clinician in selecting the correct level and frequency of 
treatment. Asthma was previously classified as mild, 
moderate or severe (4) and this classification was widely 
accepted within the asthma community. However, in the 
more recent revisions (5,14) these classifications were re- 
vised to mild intermittent, mild persistent, moderate 
persistent and severe persistent to reflect the clinical 
manifestations of asthma (Table I). Classifying asthma in 
this way is not intended to restrict the type of therapy 
received by an individual patient. It is intended as a guide 
to the level of therapy that may be required by a patient 
in order to gain symptomatic control, with a subsequent 
increase or decrease in therapy as required. Patients di- 
agnosed with any level of asthma may have mild, moder- 
ate or severe exacerbations, and these exacerbations 
need defined management (14). 
The underlying pathophysiology of asthma is defined 
by chronic inflammation of the airways (IS). Death result- 
ing from asthma is usually accompanied by massive cellu- 
lar infiltration (eosinophils, mast cells and mononuclear 
cells) in both the large and small airways (16) but exten- 
sive inflammatory changes in the airways are not re- 
stricted to severe asthma and are frequently seen even 
in mild clinical disease (17-20). These findings are consis- 
tent with the view that daily anti-inflammatory medi- 
cation should be initiated early in treatment to reduce 
the risk of irreversible airway remodelling (1,21-23). 
Asthma in children over the age of 5 years is classified 
in the same way as for adults. For infants and children 
under 5 years of age, objective measurements of lung 
function are difficult to obtain due to a lack of appropri- 
ate methods and evaluation therefore relies on the in- 
fant’s medical history, symptoms, physical examination 
and an assessment of quality of life. 
MANAGING AVARIABLE DISEASE 
The successful management of persistent asthma in- 
volves both routine clinical assessment and regular self- 
monitoring by the patient. This ongoing evaluation helps 
to determine whether the goals of therapy are being 
achieved. These goals are the same for every asthma 
patient and aim to: minimize or eliminate symptoms; 
reduce the frequency of exacerbations; reduce the need 
for emergency department visits and hospitalization; 
minimize the need for acute rescue therapy such as in- 
haled &agonists; normalize pulmonary function; estab- 
lish a normal lifestyle without limitations on activities, 
including exercise; and minimize or eliminate adverse 
effects from medication. 
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Given the variable nature of the condition, asthma 
treatment needs to be tailored to individual patients. 
This means that a patient’s treatment plan takes into ac- 
count disease severity, current symptom patterns (with- 
in the previous I2 months) and the present age of the 
patient (14). Asthma severity is often under-estimated 
and preventative therapy under-prescribed (724); this 
may result in poor asthma control and lead to an in- 
crease in rate or severity of exacerbations. It is now well 
accepted that appropriate treatment can prevent a 
substantial proportion of hospital admissions. In one 
study, approximately 74% of admissions were considered 
to be preventable (25). Prescribing even low doses of in- 
haled corticosteroids may reduce asthma mortality 
(26,27). 
Managing asthma in patients susceptible to seasonal 
variations and/or exposure to irritants can be difficult. 
For these patients, it is essential that they monitor 
symptoms carefully and undergo clinical assessment as 
needed. In addition to recognizing a worsening in their 
condition, patients need to know what action to take 
and what relief they can reasonably expect from short- 
acting bronchodilators (28). Appropriate patient inter- 
vention can only be achieved if patients are willing to 
make decisions about their own asthma care and this 
can only be achieved if they are informed about their 
condition (28). Some patients are unwilling to accept 
that there is underlying airway inflammation present 
even when the severity of the disease is reduced, and 
that this may require long-term maintenance therapy, 
This non-acceptance leads to poor adherence to daily 
anti-inflammatory medication (29). 
Current guidelines advocate a stepwise approach to 
long-term asthma treatment that places a patient at a 
certain level or step (mild intermittent, mild persistent, 
moderate persistent or severe persistent) based on cur- 
rent symptoms and recommends therapy accordingly 
(Table 2).This stepwise approach to asthma management 
involves routine treatment assessment and a step up or 
down the treatment ladder until the optimal treatment 
is attained. Stepping up can involve either a change in 
therapy or an increase in medication so that asthma con- 
trol is achieved. A step down in treatment is recom- 
mended when symptoms have been well controlled for 
at least 3 months. Stepping down is an important part of 
asthma therapy and ensures that patients are not over- 
treated. Within the guidelines, there are two approaches 
to gaining asthma control. A clinician may prescribe: 
a high level of therapy (e.g. add a short course of 
prednisolone or a higher dose of inhaled 
corticosteroids that corresponds with the patient’s 
level of asthma therapy) to establish prompt asthma 
control and then reduce the medication to a level 
that maintains symptom control; 
alternatively, a patient can start treatment at the step 
most appropriate to the level of asthma severity and 
treatment can then be ‘stepped up’ more gradually 
until control is achieved. 
The first approach should be favoured, because the 
second approach may lead to a significant delay in con- 
trolling asthma symptoms and the frequent use of rescue 
medication. This step up/step down approach to asthma 
can only achieve optimal disease management if the doc- 
tor and patient are willing to reassess the need for medi- 
cation regularly. Since many patients are under- 
diagnosed, they are most likely to receive a level of ther- 
apy that fails to control asthma symptoms and this can 
result in an over-reliance on relievers (14). This situation 
is not optimal and newer therapeutic approaches, such 
as combination treatments, which reduce the need for 
rescue medication by controlling the acute and chronic 
aspects of asthma, are being introduced. 
PHARMACOLOGICAL 
MANAGEMENT OF ASTHMA 
Inhaled corticosteroids are the mainstay of treatment 
for patients with persistent asthma (30). As potent 
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anti-inflammatory agents they effectively reduce and 
control airway inflammation and inhibit almost every as- 
pect of the inflammatory process in asthma. Inhaled cor- 
ticosteroids are effective in the majority of patients, 
irrespective of age or asthma severity, In addition to con- 
trolling asthma symptoms and improving lung function, 
they also reduce the number of exacerbations and 
asthma mortality (26). Inhaled corticosteroids are pre- 
scribed for the long-term control of asthma symptoms 
and systemic corticosteroids may be used to gain rapid 
control of symptoms along with commencing long-term 
therapy with inhaled corticosteroids (14). 
Relief from asthma symptoms is achieved by short-act- 
ing &agonists (e.g. salbutamol and terbutaline).The fre- 
quent use of these drugs is commonly used as an 
indication that anti-inflammatory treatment is inad- 
equate. An over-reliance on relief medication is common 
in patients who do not adhere to their treatment pro- 
gramme and only use a short-acting &-agonist when 
long-term therapy with a corticosteroid has been ad- 
vised. One concern is that effective bronchodilation 
through regular short-acting &agonist therapy alone 
may mask worsening airway inflammation (3l).This may 
lead to a delay in recognizing the onset or presence of a 
severe asthma attack. 
Once a patient requires quick-reljef medication every 
day, or more than 3-4 times a week, daily long-term 
medication is recommended if none is currently adminis- 
tered. In practice, this is an unnecessarily late stage to in- 
itiate anti-inflammatory therapy with inhaled steroids 
(21,32). A step up (increase of the dose of the inhaled cor- 
ticosteroid) to more effective therapy is required for 
patients already taking the prescribed doses of daily 
medication and whose inhalation technique is correct. 
Long-acting &agonists (e.g. formoterol and salmeter- 
01) have become an important part of the therapeutic 
approach to managing asthma, giving relief for more than 
I2 hours. Formoterol, however, has the advantage over 
salmeterol of being a full agonist at Pz-adrenoceptors, 
with a near maximal effect (33). Formoterol has a rapid 
onset of action similar to that of salbutamol, whereas 
salmeterol has a slow onset of action (33). Despite the 
introduction of the more selective &agonists, there is 
still concern about increased morbidity and a worsening 
in asthma control with the maintenance use of these 
agents. However, moderate long-term use of the short- 
acting &-agonists, salbutamol and terbutaline, and the 
long-acting &agonists does not appear to be associated 
with a significant worsening of asthma control or an in- 
creased frequency of acute attacks (31). 
Optimizing control in moderate and more severe 
asthma can be achieved by combining long-acting bz- 
agonists with inhaled corticosteroids, thereby treating 
both the chronic inflammation of asthma and its func- 
tional consequence-airflow limitations (34-36). A re- 
cent treatment advance is the clinical development of 
Symbicort@, which combines two such effective agents, 
budesonide (inhaled corticosteroid) and formoterol 
(long-acting &agonist with a rapid onset of action), in a 
single inhaler (37). 
Recent studies suggest that the addition of a long-act- 
ing &agonist to low-to-medium doses of inhaled corti- 
costeroid may be more effective than increasing the dose 
of the inhaled corticosteroid alone when a step up in 
treatment is required in persistent asthma (34-36).This 
finding can be explained, in part, by the fact that increas- 
ing the dose of inhaled corticosteroids according to the 
severity of the disease does not have a uniform effect on 
the different indices of asthma severity. For example, 
lung function measurements respond readily to low- 
dose inhaled corticosteroids, but their overall dose re- 
sponse is flat (38). 
The concomitant use of formoterol and budesonide 
was studied in a l-year clinical trial in patients who had 
persistent symptoms of asthma despite treatment with 
inhaled corticosteroids (36). In this study, the addition of 
formoterol to a low dose of budesonide reduced the rate 
of severe and mild exacerbations by 26% and 40%, re- 
spectively, compared with low-dose budesonide alone. 
Moreover, the addition of formoterol to low-dose budes- 
onide was more effective than the higher dose of budes- 
onide alone in improving clinical outcomes including 
lung function, symptom scores during the day and night, 
and the number of symptom-free days (36). The clinical 
benefits seen with the addition of formoterol to budeso- 
nide were irrespective of the dose of inhaled cortico- 
steroid. 
THE CHALLENGE OF INCREASING 
PATIENTAWARENESS AND 
ADHERENCE 
Adherence to prescribed therapy is a major factor in the 
successful management of asthma. In spite of significant 
advances in developing asthma medications and the in- 
troduction of patient self-management plans, many 
people are unable to manage their asthma therapy 
optimally. Patient compliance with asthma treatment has 
been repeatedly estimated at approximately 50% (39.40). 
This failure to follow medication regimens may lead to 
treatment failure or apparent lack of drug efficacy. 
The terms ‘compliance’ and ‘adherence’ are often used 
interchangeably in healthcare management without clear 
definition. In asthma management, treatment compli- 
ance implies a willingness on the part of the patient to 
follow their doctor’s instructions, but sometimes with 
little or no understanding of the disease or involvement 
in their own management strategy Treatment adher- 
ence, on the other hand, involves a commitment to the 
treatment plan and therapy is the driving factor (41.42). 
This necessitates negotiation between the patient and 
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all members of their asthma-care team. In order for op- 
timal adherence to be achieved, patients must be in- 
formed about their condition and be able to take 
appropriate therapeutic actions. Compliance is not 
enough to achieve optimal control of persistent asthma 
and all asthma care-team members should work towards 
adherence (42). 
Compliance with, or adherence to, asthma manage- 
ment plans can be improved if patients have the oppor- 
tunity to talk about their concerns, fears and expectations 
related to their asthma. Common factors associated 
with non-compliance are given inTable 3. 
Patients with asthma need to be aware of what trig- 
gers their asthma and how these factors can be avoided. 
Taking medication correctly (especially the use of in- 
halers) is a key factor in controlling symptoms. Patients 
also need to be educated about a number of issues in- 
cluding: the different types of therapy (e.g. ‘quick-relief’ 
and ‘long-term preventative’ medication); self-monitor- 
ing; and recognizing and taking correct action in the 
event of worsening asthma. The current guidelines 
strongly recommend the use of written management 
plans for the patient/patient’s family (14). 
In addition to these practical issues, there is the more 
difficult problem of changing the patient’s perception of 
his/her illness and medication. Children are particularly 
susceptible to peer pressure and opinion, and may have 
a very negative perception of their disease due to exer- 
cise intolerance which limits their ability in sporting ac- 
tivities. Children with asthma are also reported to feel 
self-pity, have low self-opinion and poor relationships 
with their peers (4). 
It is often difficult for patients to accept that asthma is 
a disease requiring long-term treatment, particularly 
when their symptoms are mild. Educating asthma 
patients about the variable nature of their condition 
and the underlying pathology is the only effective way of 
achieving long-term commitment to therapy. 
Other factors have also been identified which affect 
compliance and include: problems with inhaler devices; 
awkward medication regimens; and multipharmacother- 
apy, as well as fears about side-effects (4). In recent years, 
new designs of inhalers have been introduced which are 
easier to use for both children and adults. All patients 
need to be trained how to use inhalers correctly so that 
they receive the correct dose of medication. Devices 
which are preferred by the patient tend to increase treat- 
ment adherence. It is now well established that compli- 
cated treatment regimens are poorly adhered to in all 
fields of clinical medicine (42). Long-term treatment, mul- 
tiple therapies and frequent dosing are also predictors of 
poor compliance (39). Until recently, these factors were 
all characteristics of asthma therapy which is associated 
with poor adherence to prescribed medication (39). 
Issues of adherence can be addressed to some extent 
by patient education and counselling, but this approach 
requires huge investment in both time and money, and a 
willingness on the part of patients to become involved in 
their own care and treatment. The implementation of a 
simple treatment regimen which achieves reasonably 
well the goals of asthma therapy and makes the patient 
feel confident, is likely to be of great benefit in improving 
adherence. There will always be a minority of patients 
who are resistant to managed care, for whatever reason, 
and their asthma control will be suboptimal despite 
every effort on the part of the healthcare team. 
OPTIMIZING ASTHMA CONTROL 
Optimizing the control of asthma requires a comprehen- 
sive approach to asthma management (Table 4) (43). 
First, patients need to be correctly diagnosed early 
enough and assessed for severity. Second, individualized 
care plans need to be established from the very start of 
treatment. Once established, the treatment plan should 
be written down, discussed and reviewed with the 
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patient so that the patient is able to implement agreed 
treatment strategies. Clinicians need to ensure that both 
patients and healthcare team members are well edu- 
cated about asthma and motivated so that treatment 
plans can be followed correctly. Treatment plans should 
be simple and easy to follow. Finally, good co-operation 
between patient, doctor and the healthcare team should 
lead to better long-term optimal control of this variable 
disease, with improvement in the patient’s quality of life. 
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